How to buy Biofrontera stock

Biofrontera AG is a biotechnology business based in the US. Biofrontera shares (BFRA) are listed on the NASDAQ and all prices are listed in US Dollars. Biofrontera employs 149 staff and has a trailing 12-month revenue of around 0.00.

Biofrontera share price

Use our graph to track the performance of BFRA stocks over time.

Biofrontera shares at a glance

• Key figures

Information last updated 2021-04-30.

52-week range	$4.67 - $41.92
50-day moving average	$5.60
200-day moving average	$6.86
Wall St. target price	$8.00
PE ratio	N/A
Dividend yield	N/A (0.37%)
Earnings per share (TTM)	$-0.76

Buy Biofrontera shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Biofrontera stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Biofrontera AG by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Biofrontera financials

Revenue TTM	$30.3 million
Gross profit TTM	$26.8 million
Return on assets TTM	-6.11%
Return on equity TTM	-150.29%
Profit margin	-42.92%
Book value	$0.31
Market capitalisation	$156.5 million

TTM: trailing 12 months

Shorting Biofrontera shares

There are currently 2,290 Biofrontera shares held short by investors – that's known as Biofrontera's "short interest". This figure is 15.6% down from 2,714 last month.

There are a few different ways that this level of interest in shorting Biofrontera shares can be evaluated.

Biofrontera's "short interest ratio" (SIR)

Biofrontera's "short interest ratio" (SIR) is the quantity of Biofrontera shares currently shorted divided by the average quantity of Biofrontera shares traded daily (recently around 57250). Biofrontera's SIR currently stands at 0.04. In other words for every 100,000 Biofrontera shares traded daily on the market, roughly 40 shares are currently held short.

However Biofrontera's short interest can also be evaluated against the total number of Biofrontera shares, or, against the total number of tradable Biofrontera shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Biofrontera's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Biofrontera shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Biofrontera shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Biofrontera.

Find out more about how you can short Biofrontera stock.

Biofrontera share dividends

We're not expecting Biofrontera to pay a dividend over the next 12 months.

Biofrontera share price volatility

Over the last 12 months, Biofrontera's shares have ranged in value from as little as $4.67 up to $41.9167. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biofrontera's is 1.4684. This would suggest that Biofrontera's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Biofrontera overview

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co.

Frequently asked questions

What percentage of Biofrontera is owned by institutions?
Currently 0.055% of Biofrontera shares are held by institutions. How many people work for Biofrontera?
Latest data suggests 149 work at Biofrontera. When does the fiscal year end for Biofrontera?
Biofrontera's fiscal year ends in December. Where is Biofrontera based?
Biofrontera's address is: Hemmelrather Weg 201, Leverkusen, Germany, 51377 What is Biofrontera's ISIN number?
Biofrontera's international securities identification number is: US09075G1058 What is Biofrontera's CUSIP number?
Biofrontera's Committee on Uniform Securities Identification Procedures number is: 09075G105